Background: Studies report conflicting evidence regarding the existence of a DCIS-associated premalignant pathway in BRCA mutation carriers. We aimed to examine the prevalence, phenotype, and expression of oncodrivers in pure DCIS (pDCIS) and invasive breast cancer with concurrent DCIS (IBC + DCIS) in mutation carriers.
Methods: A cohort of BRCA1 and BRCA2 mutation carriers >18 years old who underwent surgery for breast cancer at an academic hospital (1992-2011) and had pathology available for review were included for study. Invasive breast cancer (IBC) and DCIS were stained for ER, PR, HER1, HER2, and HER3, and C-MET. DCIS prevalence was evaluated. Correlation of IBC and DCIS phenotypes was evaluated in patients with IBC + DCIS. DCIS and IBC expression of tumor markers were examined by BRCA mutation.
Results: We identified 114 breast tumors. Of all BRCA1-associated tumors, 21.1 % were pDCIS and 63.4 % were IBC + DCIS. Of all BRCA2-associated tumors, 23.3 % were pDCIS and 60.5 % were IBC + DCIS. In BRCA1 and BRCA2 mutation carriers with IBC + DCIS, there was a significant correlation in ER, PR, and HER3 expression between the DCIS and IBC components. Most BRCA1-associated DCIS did not express ER, PR or HER2, while most BRCA2-associated DCIS did express ER and PR. BRCA1- as well as BRCA2-associated DCIS had expression of HER3 and C-MET.
Conclusions: The majority of BRCA-associated tumors had DCIS present. Concordance of DCIS and IBC phenotypes was high, arguing for the existence of a DCIS-associated premalignant pathway. Oncodrivers HER3 and C-MET were expressed in the DCIS of mutation carriers, suggesting an opportunity for prevention strategies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619378 | PMC |
| http://dx.doi.org/10.1186/s12967-015-0698-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
From ductal carcinoma in situ to invasive breast cancer: the prognostic value of the extracellular microenvironment.
J Exp Clin Cancer Res
December 2024
Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
Ductal carcinoma in situ (DCIS) is a noninvasive breast disease that variably progresses to invasive breast cancer (IBC). Given the unpredictability of this progression, most DCIS patients are aggressively managed similar to IBC patients. Undoubtedly, this treatment paradigm places many DCIS patients at risk of overtreatment and its significant consequences.
View Article and Find Full Text PDFMultimodal genome-wide survey of progressing and non-progressing breast ductal carcinoma in-situ.
Breast Cancer Res
December 2024
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Article Synopsis
- Ductal carcinoma in-situ (DCIS) is a non-invasive breast cancer type that makes up about 25% of breast cancer cases, but it often leads to unnecessary aggressive treatment despite many cases never progressing to invasive cancer.
- A study analyzed 197 breast tissue samples to explore molecular changes in DCIS, using techniques like mRNA expression and DNA analysis to compare progressing versus non-progressing cases.
- The research found significant molecular differences among DCIS subtypes and between DCIS and invasive breast cancer, highlighting the complexity of DCIS and the need for more tailored approaches to assess risk and treatment.
Surgical treatment after neoadjuvant systemic therapy for HER2-positive invasive breast cancer in the Netherlands: 10-Year trends and the influence an accompanying DCIS component.
Breast
November 2024
Department of Surgery, Maastricht University Medical Centre+, Maastricht, the Netherlands; GROW - Research Institute for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, the Netherlands.
Background: The presence of a DCIS component accompanying invasive breast cancer (IBC) is associated with a higher rate of primary mastectomy compared to IBC without DCIS. After neoadjuvant systemic therapy (NST), HER2+ IBC patients show high response rates, allowing for increasing breast-conserving surgery rates. The aim of this study was to examine surgical trends after NST in a Dutch nationwide HER2+ cohort, and the influence of a DCIS component on mastectomy rate.
View Article and Find Full Text PDFCorrelation of tumor budding with a novel and other established prognostic parameters in patients with invasive breast carcinoma.
Indian J Pathol Microbiol
October 2024
Department of Pathology, MGM Medical College and Hospital, Aurangabad, Maharashtra, India.
Context: Breast cancer is the most common malignancy among women. Established prognostic markers in breast carcinomas include tumor size, histologic grade, nodal status, lymphovascular invasion, perineural invasion, hormone receptor status, HER-2 status, and age.
Aim: To correlate peripheral tumor budding (pTB) with stromal tumor-infiltrating lymphocytes (sTILs) and established prognostic factors in invasive breast carcinoma.
Article Synopsis
- A study using single-cell RNA sequencing analyzed ductal carcinoma in situ (DCIS) to understand its growth mechanisms and how it may progress to invasive cancer.
- Researchers identified a mix of cancerous and normal epithelial cells, uncovering significant genetic diversity and different cell states driven by estrogen receptor expression.
- The findings suggest that changes in specific cell states and loss of basement membrane integrity are linked to the transition from DCIS to invasive breast cancer, highlighting the biological complexity of preinvasive breast diseases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!